What is she best known for?
The fields of study she is best known for:
Her scientific interests lie mostly in Cancer research, Leukemia, Myeloid leukemia, Immunology and Internal medicine.
Her studies in Cancer research integrate themes in fields like Gene expression profiling, Progenitor cell, Cancer cell, Chromosomal translocation and Breast cancer.
Her Leukemia research includes elements of Myeloid, Fluorescence in situ hybridization, Gene mutation and Pathology.
Her Myeloid leukemia study combines topics from a wide range of disciplines, such as Molecular biology, Alpha interferon, NPM1 and Cytogenetics.
Brigitte Schlegelberger has researched Immunology in several fields, including Hematopoietic stem cell transplantation, Haematopoiesis, Bone marrow failure and Glomerulonephritis.
Her Internal medicine research includes themes of Gastroenterology and Oncology.
Her most cited work include:
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia (1309 citations)
- Oncogene-induced senescence as an initial barrier in lymphoma development (948 citations)
- RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group (343 citations)
What are the main themes of her work throughout her whole career to date?
Brigitte Schlegelberger mostly deals with Internal medicine, Oncology, Cancer research, Immunology and Myeloid leukemia.
Brigitte Schlegelberger frequently studies issues relating to NPM1 and Internal medicine.
Her Oncology research focuses on Pathology and how it relates to Fluorescence in situ hybridization.
Her Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Gene, Cancer and Signal transduction.
Her work carried out in the field of Myeloid leukemia brings together such families of science as Molecular biology and Chromosomal translocation.
As a part of the same scientific family, Brigitte Schlegelberger mostly works in the field of Leukemia, focusing on Myeloid and, on occasion, Haematopoiesis.
She most often published in these fields:
- Internal medicine (35.54%)
- Oncology (25.28%)
- Cancer research (25.06%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (35.54%)
- Oncology (25.28%)
- Genetics (15.49%)
In recent papers she was focusing on the following fields of study:
Brigitte Schlegelberger mainly focuses on Internal medicine, Oncology, Genetics, Cancer research and Myeloid leukemia.
Her Transplantation and Leukemia study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
Her study in Leukemia is interdisciplinary in nature, drawing from both Gene mutation and Chromosome abnormality.
Brigitte Schlegelberger interconnects Hematopoietic stem cell transplantation, Fusion transcript, Venetoclax, Myelodysplastic syndromes and Trisomy 8 in the investigation of issues within Oncology.
Her Cancer research research incorporates themes from Breast cancer, Aneuploidy and Neuroblastoma RAS viral oncogene homolog.
Her Myeloid leukemia study also includes
- Chromosomal translocation which intersects with area such as Chromosome and Molecular biology,
- Karyotype that intertwine with fields like Fluorescence in situ hybridization.
Between 2017 and 2021, her most popular works were:
- Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. (101 citations)
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. (41 citations)
- Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. (31 citations)
In her most recent research, the most cited papers focused on:
Her primary areas of investigation include Internal medicine, Transplantation, Oncology, Ovarian cancer and Breast cancer.
She regularly ties together related areas like Gastroenterology in her Internal medicine studies.
Her Transplantation study integrates concerns from other disciplines, such as Leukemia and Cumulative incidence.
Her research on Leukemia frequently connects to adjacent areas such as Survival rate.
Brigitte Schlegelberger interconnects Odds ratio, Family Cancer History, Germline mutation and Triple-negative breast cancer in the investigation of issues within Oncology.
PMS2 is frequently linked to Cancer research in her study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
